## **Healthy People 2010 Operational Definition**

13-13. Increase the proportion of HIV-infected adolescents and adults who receive testing, treatment, and prophylaxis consistent with current Public Health Service treatment guidelines.

## **Prophylaxis**

13-13f. Mycobacterium avium complex (MAC) prophylaxis.

National Data Source Adult Spectrum of Disease (ASD) surveillance

project, CDC, NCHSTP (11 U.S. cities—see

Comments).

State Data Source Not identified.

**Healthy People 2000** 

**Objective** 

Not applicable.

Changes since the

2000 Publication

Revised baseline (see Comments).

Measure Percent.

**Baseline (Year)** 53 (1997) (selected sites—see Comments).

Target 95

**Target-Setting Method** An improvement to the same percentage as that

projected for Pneumocystis carinii pneumonia

prophylaxis.

For a discussion of target-setting methods, see Part

A, section 4.

**Numerator** Number of persons enrolled in the ASD surveillance

project with at least one clinic visit, had a minimum cd4 cell count of less than 50, had no history of

MAC, and received any appropriate MAC

prophylaxis, all in the past year.

**Denominator** Number of persons enrolled in the ASD surveillance

project with at least one clinic visit, who had a minimum cd4 cell count of less than 50, and no

history of MAC in the past year.

**Population Targeted** Residents of selected sites—see Comments.

Questions Used To Obtain the National Baseline Data Not applicable.

**Expected Periodicity** 

Annual.

Comments

MAC prophylaxis is defined as medications (rifabutin, clarithromycin, or azithromycin) given to prevent the occurrence of MAC. The case definition of MAC is provided by CDC.<sup>1</sup>

ASD data were standardized to national AIDS surveillance data by age, race, sex, country of birth, year of AIDS diagnosis, and HIV exposure mode. Exposure modes in AIDS surveillance were redistributed to adjust for cases with risk that were not reported or identified.

ASD data represent more than 100 sites in 11 U.S. cities. ASD collects demographic, clinical, laboratory, surveillance, and other related data on HIV-infected persons aged 13 years and older.

Data from ASD represent only persons with HIV who are in care at participating ASD facilities. Treatment interventions include viral load testing, TB skin testing, HAART, PCP prophylaxis, MAC prophylaxis, and pneumococcal vaccination.

The original 1997 baseline of 44 percent was revised to 53 percent after the Healthy People 2010 Midcourse Review. The original target of 95 percent did not change.

See Appendix A for focus area contact information.

## References

1. CDC. Morbidity and Mortality Weekly Report 41(RR-17):1-19, 1992.

Operational Definition: Objective 13-13f